Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ralco Nutrition Inc. is currently addressing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating that the portfolio's current challenges are spread across different technical specialties. This distribution requires a strategy that accounts for varying examiner perspectives and art unit norms. Practitioners must navigate different procedural expectations as they address the unique requirements of each art unit involved in the nutrition and pharmaceutical sector. This structure suggests that the company's intellectual property covers different technical sub-fields within the broader biotechnology category.
SAEED, ALI S is the busiest examiner, with 1 pending office action under review. Since the 2 pending actions are split between 2 distinct examiners, no single individual controls the majority of the portfolio's current prosecution. Practitioners must manage the 2 distinct art units separately, as each may have different procedural expectations for nutrition-related filings. Successfully resolving these matters will depend on tailoring responses to the specific technical feedback provided within the 2 distinct art units and understanding the individual tendencies of each examiner. This balance allows for a diversified approach to prosecution, though it requires tracking the specific tendencies of both examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, ALI S | 1 | 31.3% | +35.8% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18208496 | MACRONUTRIENT COMPOUNDS | SAEED, ALI S | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17215677 | FEED MITIGANT COMPOSITIONS FOR INACTIVATING SWINE VIRUSES AND RELATED METHODS | BAEK, BONG-SOOK | 6d |
| 18208496 | MACRONUTRIENT COMPOUNDS | SAEED, ALI S | 12d |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18208496 | MACRONUTRIENT COMPOUNDS | SAEED, ALI S | 1616 | §103§112 | Final Rejection | 12d | Pending | Jun 12, 2023 |
| 17215677 | FEED MITIGANT COMPOSITIONS FOR INACTIVATING SWINE VIRUSES AND RELATED METHODS | BAEK, BONG-SOOK | 1611 | §103DP | Final Rejection | 6d | Pending | Mar 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial